The Luteal Week on a GLP-1

The short version

Most of what is written about GLP-1s and the menstrual cycle runs one direction: what the drug does to your cycle. That is a real subject and it is covered on GLP-1s, the menstrual cycle and reproductive hormones — ovulation, cycle regularity, contraception.

This page runs the other direction. What does your cycle do to your appetite, and should any of it change how you take the drug?

Two answers, and the second is the one people get wrong. The luteal rise in appetite is real and has been quantified. And the idea that follows naturally from it — time the injection to the hungry week — does not survive contact with either the pharmacology or the only study that has looked.

The luteal rise is real, and it has a number

A 2025 systematic review and meta-analysis pooled 15 datasets to compare energy intake in the luteal phase against the follicular phase¹.

So the week before your period, on average, women in these studies ate meaningfully more. Not imagined, not weakness — a measured, repeatable population effect.

Now the limit that decides how much of it applies to you, and it is a large one. Every woman in that analysis had a body mass index between 18.5 and 25. That is, by design, not the population that starts a GLP-1. Nobody has run the same measurement in women with obesity, and the authors also flag repeated methodological inconsistencies across the studies they pooled and ask for better practice in future work. Treat 168 kcal as a real signal with an uncertain size, not as a figure that describes your week.

It is not evenly distributed

A 2025 study of 150 women looked at whether premenstrual syndrome changes the picture, and found that it does². Women with PMS scored significantly higher on a hedonic hunger scale during the luteal phase than women without it — 3.5 versus 2.9 — and energy intake rose significantly in the PMS group during that phase.

Hedonic hunger is the wanting-it kind rather than the needing-it kind, which matches what people actually describe. The average age was 22, the data were self-reported through a web questionnaire, and anthropometric measurements were taken from participants' own statements, so this is a soft measurement of a real thing rather than a hard one.

The useful part is that the luteal effect appears concentrated rather than universal. If your luteal week is uneventful, nothing here says it should not be.

What that means for a week on a GLP-1

Mostly it means this: if your intake drifts up in the week before your period while you are on one of these drugs, that is a documented physiological pattern arriving on schedule. It is not the medication failing, and it is not a reason to change the dose.

It is worth knowing because the alternative interpretation — that the drug has stopped working — is the one that sends people to raise their dose early or to conclude they are a non-responder, on the strength of one week in four.

Timing the injection to your cycle: why it does not follow

This is the idea the section above invites, and it is worth taking seriously enough to knock down properly.

The only study that has tested it is in rats. A 2026 paper found that GLP-1 receptor expression in the brainstem varied across the estrous cycle, and that giving liraglutide or semaglutide during particular phases suppressed food intake more, with semaglutide producing greater weight loss when it was given only in those phases³. The authors themselves suggest possible translational implications for timing across the menstrual cycle.

Two things stop that becoming advice.

The favorable phase is not the one you would guess. The effect was potentiated in proestrus and estrus — the phases in which estradiol is high, corresponding roughly to the days around and before ovulation in a human cycle. That is not the luteal week. If these findings translate at all, they point away from dosing for the hungry week, not toward it.

And a weekly drug cannot be timed to a cycle phase anyway. Semaglutide and tirzepatide are taken once weekly and held at steady state; the drug is present in roughly similar amounts every day of your cycle. There is no dose day that falls inside one phase and outside another. The rat experiments used acute injections and phase-restricted dosing, which is not how any person takes this medication.

So: interesting biology, genuinely worth following, and not something to act on.

What is actually worth doing

Expect the week rather than being ambushed by it. Knowing that appetite climbs on a schedule is most of the benefit.

Do not read one week as treatment failure. Judge the medication over months, which is the timescale its trials use.

Do not change the dose or the day on your own. Dose changes belong with whoever prescribes, and there is no evidence base for a cycle-timed schedule.

Track it if you want to know. Your own pattern is more informative to you than a pooled average from women at a different body weight.

Where this sits on the evidence scale

Energy intake is higher in the luteal phase: moderate. A meta-analysis of 15 datasets and 330 women, statistically significant, but conducted in women of normal body mass index and limited by inconsistent methods across the source studies.

The effect is larger in women with PMS: low. One study, 150 women, self-reported through questionnaires, mean age 22.

Cycle phase changes how well a GLP-1 works: no human evidence. The finding exists in rats, in the opposite phase from the intuitive one, and has never been tested in people.

Timing a weekly injection to a cycle phase: no evidence, and no mechanism. A drug held at steady state is not present differently in different weeks, so there is nothing for the timing to act on. Any research that changes this will have to start with a human trial that does not yet exist.